本文選題：腎癌　切入點：透明細胞癌　出處：《蘭州大學(xué)》2014年碩士論文

【摘要】：腎癌,又稱腎細胞癌(renal cell carcinoma, RCC),其發(fā)病率占全身惡性腫瘤的3%,在病理上75%表現(xiàn)為透明細胞癌,不同病理類型的腎癌具有不同的臨床特點、治療方案和預(yù)后。血尿、疼痛、腫塊稱為腎癌的三聯(lián)征。臨床上有30%-50%的病例系偶然發(fā)現(xiàn)的無癥狀患者,而有癥狀者在診斷時大都已有或?qū)l(fā)生轉(zhuǎn)移病變。目前腎癌的主要治療方法是外科手術(shù)根治,但既使早期患者手術(shù)治療后,仍有部分患者將發(fā)生轉(zhuǎn)移。轉(zhuǎn)移性腎癌預(yù)后較差,對放化療等治療不敏感,3年平均存活率低于5%。因此,深入了解腎癌的發(fā)病機制,并在此基礎(chǔ)上探索早期診斷和治療方法有著重要的意義。 目的：觀察并檢測腦組織特異性血管生成抑制因子1(BAI1)基因在癌旁組織、腎透明細胞癌、腎乳頭狀細胞癌及嫌色細胞癌組織中的表達情況,分析BAI1表達與各臨床病理參數(shù)之間的相關(guān)性,探討B(tài)AI1基因在腎細胞癌發(fā)生、發(fā)展中的作用,以期為RCC的診斷及治療提供幫助。 方法：1.應(yīng)用免疫組織化學(xué)PV-9001法檢測BAI1在60例透明細胞癌、15例乳頭狀細胞癌、13例嫌色細胞癌和27例正常腎臟組織中的表達情況。2.應(yīng)用逆轉(zhuǎn)錄-聚合酶鏈反應(yīng)(reverse transcription-polymerase chain reaction; RT-PCR)檢測20例癌旁組織、20例腎細胞癌組織中BAI1的mRNA含量。 結(jié)果：1.BAI1在各種病理類型的RCC中表達比癌旁組織中陽性表達率明顯降低,其差異具有統(tǒng)計學(xué)意義(P0.05)； 2.BAI1在RCC中的表達與年齡、性別無關(guān)(P0.05),但與RCC的Robson分期、病理分級及是否淋巴轉(zhuǎn)移有關(guān)(P0.05)。 3.BAI1在腎透明細胞癌中表達與Robson分期呈負相關(guān),其差異具有明顯統(tǒng)計學(xué)意義(P0.05)。 4. BAIlmRNA在RCC組織中的表達顯著低于癌旁組織,其差異具有統(tǒng)計學(xué)意義(P0.05)： 結(jié)論：BAI1基因和mRNA在正常腎癌組織表達陽性率明顯高于RCC組織,其表達與腫瘤的分化程度、臨床分期、淋巴結(jié)轉(zhuǎn)移等臨床病理因素存在密切關(guān)系,提示BAI1的低表達可能參與RCC的發(fā)生發(fā)展,并與RCC的侵襲、轉(zhuǎn)移有關(guān)。在RCC中檢測BAI1基因的表達可能對判斷腫瘤的嚴(yán)重程度及診斷治療提供一定的幫助。
[Abstract]:Renal cell carcinoma (RCC), also called renal cell carcinoma (RCC), accounts for 3% of all malignant tumors in the body, and 75% of its pathological manifestations are clear cell carcinoma. Different pathological types of renal carcinoma have different clinical characteristics, treatment plan and prognosis, hematuria, pain, etc. The mass is called the triple sign of renal cell carcinoma. Clinically, 30 to 50% of the cases are asymptomatic patients found by chance, and most of the patients with symptoms have or will have metastases at the time of diagnosis. At present, the main treatment for renal cell carcinoma is radical surgical treatment. However, even after early surgical treatment, some patients will still have metastasis. The prognosis of metastatic renal cell carcinoma is poor, it is insensitive to radiotherapy and chemotherapy, and the average survival rate of 3 years is lower than 5%. Therefore, we should deeply understand the pathogenesis of renal cell carcinoma. On this basis, it is of great significance to explore the early diagnosis and treatment methods. Objective: to observe and detect the expression of brain tissue specific angiogenesis inhibitor 1 (BAI1) gene in paracancerous tissues, renal clear cell carcinoma, renal papillary cell carcinoma and chromophobe cell carcinoma. To analyze the correlation between the expression of BAI1 and the clinicopathological parameters, and to explore the role of BAI1 gene in the development and development of renal cell carcinoma, in order to provide help for the diagnosis and treatment of RCC. Methods 1. Immunohistochemical PV-9001 method was used to detect the expression of BAI1 in 15 cases of papillary cell carcinoma and 13 cases of chromophobe cell carcinoma and 27 cases of normal kidney tissue. 2. Reverse transcription-polymerase chain reaction (RT-PCR) reverse transcription-polymerase was used to detect the expression of BAI1 in 15 cases of papillary cell carcinoma and 13 cases of chromophobe cell carcinoma and 27 cases of normal renal tissues. Chain reactionation (RT-PCR) was used to detect the mRNA content of BAI1 in 20 cases of renal cell carcinoma (RCC). Results 1. The positive expression rate of BAI1 in RCC was significantly lower than that in paracancerous tissues, and the difference was statistically significant (P 0.05). The expression of 2.BAI1 in RCC was not related to age and sex, but was related to the Robson stage, pathological grade and lymphatic metastasis of RCC. The expression of 3.BAI1 in renal clear cell carcinoma was negatively correlated with Robson stage, and the difference was statistically significant (P 0.05). 4. The expression of BAIlmRNA in RCC was significantly lower than that in paracancerous tissues, and the difference was statistically significant (P 0.05). Conclusion the positive rate of the expression of the mRNA gene in normal renal cell carcinoma tissue is significantly higher than that in the normal renal cell carcinoma tissue. It is closely related to the degree of tumor differentiation, clinical stage, lymph node metastasis and other clinicopathological factors. The results suggest that the low expression of BAI1 may be involved in the occurrence and development of RCC, and may be related to the invasion and metastasis of RCC. The detection of BAI1 gene expression in RCC may be helpful in judging the severity of tumor and in diagnosis and treatment.
【學(xué)位授予單位】：蘭州大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R737.11

【參考文獻】

相關(guān)期刊論文 前10條

1 傅占江;核酸擴增檢測技術(shù)的研究進展[J];國外醫(yī)學(xué).臨床生物化學(xué)與檢驗學(xué)分冊;2002年01期

2 王慧;江鋒;葉永安;李為東;閔樂泉;;一種新的免疫組化圖像分割算法研究[J];計算機應(yīng)用與軟件;2011年06期

3 歐陽松應(yīng),楊冬,歐陽紅生,馬鶴雯;實時熒光定量PCR技術(shù)及其應(yīng)用[J];生命的化學(xué);2004年01期

4 王志華,張智清,申寶忠,李瑩;BAI1基因在腸癌細胞的表達及抗血管生成作用[J];實用腫瘤學(xué)雜志;2003年01期

5 劉穎,凌世淦,于繼云;腎癌相關(guān)基因的研究進展[J];細胞與分子免疫學(xué)雜志;2005年S1期

6 蔡霞;定量PCR技術(shù)及其應(yīng)用現(xiàn)狀[J];現(xiàn)代診斷與治療;2005年02期

7 王志華;康熙雄;張智清;申寶忠;李瑩;;腸癌細胞BAI1基因表達的檢測及其抗腫瘤作用[J];世界華人消化雜志;2003年06期

8 畢新剛,馬建輝,王明榮;家族性腎癌遺傳學(xué)研究進展[J];中華泌尿外科雜志;2003年12期

9 張強,梁麗莉,席志軍,丁義,佟明,張志文,郭應(yīng)祿,李鐘,陳琳;腎癌特異相關(guān)新基因GYLZ-RCC18的克隆及功能研究(英文)[J];Chinese Medical Journal;2002年05期

10 張華,許叔祥;定量聚合酶鏈反應(yīng)的研究進展與臨床應(yīng)用[J];中華檢驗醫(yī)學(xué)雜志;2000年02期

，

本文編號：1679570